<code id='78F55297BF'></code><style id='78F55297BF'></style>
    • <acronym id='78F55297BF'></acronym>
      <center id='78F55297BF'><center id='78F55297BF'><tfoot id='78F55297BF'></tfoot></center><abbr id='78F55297BF'><dir id='78F55297BF'><tfoot id='78F55297BF'></tfoot><noframes id='78F55297BF'>

    • <optgroup id='78F55297BF'><strike id='78F55297BF'><sup id='78F55297BF'></sup></strike><code id='78F55297BF'></code></optgroup>
        1. <b id='78F55297BF'><label id='78F55297BF'><select id='78F55297BF'><dt id='78F55297BF'><span id='78F55297BF'></span></dt></select></label></b><u id='78F55297BF'></u>
          <i id='78F55297BF'><strike id='78F55297BF'><tt id='78F55297BF'><pre id='78F55297BF'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

          A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

          advertisement

          With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive